Weight-loss drug may lower risk of heart attacks and infections

For people with excess weight, type 2 diabetes, and heart disease, using the GLP-1 drug tirzepatide (Mounjaro, Zepbound) may lower the risk of heart attack, infection, and death from any cause more than taking an older drug, sitagliptin (Januvia), according to a 2026 study.